{"id":518075,"date":"2021-07-27T08:04:36","date_gmt":"2021-07-27T12:04:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/"},"modified":"2021-07-27T08:04:36","modified_gmt":"2021-07-27T12:04:36","slug":"vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/","title":{"rendered":"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BRIDGEWATER, N.J., July  27, 2021  (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.<\/p>\n<p>\n        <strong>Conference Call Details:<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u>Thursday, August 12<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <sup><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>th<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/sup><br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u> @ 8:30am Eastern Time<\/u><br \/>\n          <\/em><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%\">Toll Free:<\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%\">877-256-3294<\/td>\n<\/tr>\n<tr>\n<td>International:<\/td>\n<td>212-231-2918<\/td>\n<\/tr>\n<tr>\n<td>Conference ID:<\/td>\n<td>21995997<\/td>\n<\/tr>\n<tr>\n<td>Webcast:<\/td>\n<td>\n            <a href=\"http:\/\/public.viavid.com\/index.php?id=145705\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/public.viavid.com\/index.php?id=145705<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>A replay of the call will be archived on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qOuLWTWOOue1LI3Zk3Q0TBdVwxreMgHUnuXTfJEj61MK0HCw_PGixxb24VOu84QQRP3KTIEAZGYa_OZBxnzjJFxpkTS4LfOSI-2BRsmtcJc=\" rel=\"nofollow noopener\" target=\"_blank\">www.vynetherapeutics.com<\/a> after the conference call.<\/p>\n<p>\n        <strong>About VYNE Therapeutics Inc.<\/strong><br \/>\n        <br \/>VYNE\u2019s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.<\/p>\n<p>With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST\u2122), and has received FDA approval for AMZEEQ\u00ae (minocycline) topical foam, 4%, the world\u2019s first topical minocycline, and for ZILXI\u00ae (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea.\u00a0For more information about our approved products, please see AMZEEQ\u2019s Full Prescribing Information at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CHcfTMZgV9g-b9VrgGC7vopJYpAe12q1x78kh7XtPOKbNne1-MdICo-KNuQ8dwpn-8gcZgvMtwG0ivGlxtEztg==\" rel=\"nofollow noopener\" target=\"_blank\">AMZEEQ.com<\/a> and ZILXI\u2019s Full Prescribing Information at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=stj8v6DQ_wsBer-wKDFq6VCUAHbN9jd91yo7cmuiWq-4ZrkAoq6fe0f_NxGhuGJQWcUIuuLcsAxdpo73XUnojtfd5NqTfDx9X5NvIiNxuV3CC_gPyFIOrET90bg3jKNQeC5ZUwu2iue3MLn8xAaM9eCklNdET-Fa7pAYROFjBjlAU8-fIR1j9ijDyAkKDxJttUCHfaF-9vXdOV0B9CXxrIm4Vk0fu0lcWy01Zx5poXI=\" rel=\"nofollow noopener\" target=\"_blank\">ZILXI.com<\/a>.<\/p>\n<p>For more information about VYNE Therapeutics Inc. or its investigational products, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qOuLWTWOOue1LI3Zk3Q0TBdVwxreMgHUnuXTfJEj61OKTevKn5gk8B-7tt6gtkcqZzAHMOs-qWXOLKxYBgnaaNTD9oV6zoKXoOjyq3i1aTU=\" rel=\"nofollow noopener\" target=\"_blank\">www.vynetherapeutics.com<\/a> or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE\u2019s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.<\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors, LLC<br \/>646-889-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=APhl29QwWPd7BfG_Q6s1addqiBvbd8w4o88QUEXkzCqL-k6l5-1kXpYD3p-FcZMilw-fBUmjP9qfBcrG8Ax0-EDCLQij8FUpzVKRJROvkyTFrWhrDawR8q_xOI5PGnQG\" rel=\"nofollow noopener\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>Tyler Zeronda<br \/>VYNE Therapeutics<br \/>908-458-9106<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_-7P4y4IReT4AJKsjx4rbZ8PDGOEsGg_adpL4Y8NqDE_cUNf6dBogirHhtytxGvwS9BvTccP-mSrGaSPPk1IUWAHwSnNUL98eTmc0ZnHg0=\" rel=\"nofollow noopener\" target=\"_blank\">Tyler.Zeronda@vynetx.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7d7bc311-963f-4b4f-8054-0399e873d9aa\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Thursday, August 12 th @ 8:30am Eastern Time Toll Free: 877-256-3294 International: 212-231-2918 Conference ID: 21995997 Webcast: http:\/\/public.viavid.com\/index.php?id=145705 A replay of the call will be archived on the Company\u2019s website at www.vynetherapeutics.com after the conference call. About VYNE Therapeutics Inc. VYNE\u2019s mission is to improve the lives of patients by developing proprietary, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-518075","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Thursday, August 12 th @ 8:30am Eastern Time Toll Free: 877-256-3294 International: 212-231-2918 Conference ID: 21995997 Webcast: http:\/\/public.viavid.com\/index.php?id=145705 A replay of the call will be archived on the Company\u2019s website at www.vynetherapeutics.com after the conference call. About VYNE Therapeutics Inc. VYNE\u2019s mission is to improve the lives of patients by developing proprietary, &hellip; Continue reading &quot;VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-27T12:04:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021\",\"datePublished\":\"2021-07-27T12:04:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/\"},\"wordCount\":316,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/\",\"name\":\"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=\",\"datePublished\":\"2021-07-27T12:04:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/","og_locale":"en_US","og_type":"article","og_title":"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 - Market Newsdesk","og_description":"BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) &#8212; VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Thursday, August 12 th @ 8:30am Eastern Time Toll Free: 877-256-3294 International: 212-231-2918 Conference ID: 21995997 Webcast: http:\/\/public.viavid.com\/index.php?id=145705 A replay of the call will be archived on the Company\u2019s website at www.vynetherapeutics.com after the conference call. About VYNE Therapeutics Inc. VYNE\u2019s mission is to improve the lives of patients by developing proprietary, &hellip; Continue reading \"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-27T12:04:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021","datePublished":"2021-07-27T12:04:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/"},"wordCount":316,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/","name":"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=","datePublished":"2021-07-27T12:04:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NzAzNSM0MzE1NzI4IzIwOTM4MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-report-second-quarter-2021-financial-results-on-august-12-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/518075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=518075"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/518075\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=518075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=518075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=518075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}